Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study

Autor: Windecker, Stephan, Tijssen, Jan, Giustino, Gennaro, Guimarães, Ana H.C., Mehran, Roxana, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C., Baber, Usman, van Es, Gerrit-Anne, Wildgoose, Peter, Volkl, Albert A., Zazula, Ana, Thomitzek, Karen, Hemmrich, Melanie, Dangas, George D.

Publikováno v: In American Heart Journal February 2017 184:81-87

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Autor: Dangas, George D., Tijssen, Jan G. P., Wöhrle, Jochen, Søndergaard, Lars, Gilard, Martine, Möllmann, Helge, Makkar, Raj R., Herrmann, Howard C., Giustino, Gennaro, Baldus, Stephan, de Backer, Ole, Guimarães, Ana H. C., Gullestad, Lars, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raúl, Schäfer, Ulrich, Seeger, Julia, Tchétché, Didier, Thomitzek, Karen, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C., Wildgoose, Peter, Volkl, Albert A., Zazula, Ana, van Amsterdam, Ronald G. M., Mehran, Roxana, Windecker, Stephan, Dangas, G. D., Windecker, S., Mehran, R., Tijssen, J. G. P., Welsh, R. C., Vranckx, P., Valgimigli, M., van Amsterdam, R. G. M., Thomitzek, K., Wildgoose, P., Colombo, A., Prendergast, B., Makkar, R., Mack, M., Webb, J., Marx, Steven O., Corvaja, Nicola, Ghodsi, Newsha, DiStefano, Douglas, Kaufman, David

Publikováno v: Dangas, George D; Tijssen, Jan G P; Wöhrle, Jochen; Søndergaard, Lars; Gilard, Martine; Möllmann, Helge; Makkar, Raj R; Herrmann, Howard C; Giustino, Gennaro; Baldus, Stephan; De Backer, Ole; Guimarães, Ana H C; Gullestad, Lars; Kini, Annapoorna; von Lewinski, Dirk; Mack, Michael; Moreno, Raúl; Schäfer, Ulrich; Seeger, Julia; Tchétché, Didier; ... (2020). A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. The New England journal of medicine, 382(2), pp. 120-129. Massachusetts Medical Society 10.1056/NEJMoa1911425
Article
Dipòsit Digital de la UB
Universidad de Barcelona
New England journal of medicine, 382(2), 120-129. Massachussetts Medical Society
Dangas, G D, Tijssen, J G P, Wöhrle, J, Søndergaard, L, Gilard, M, Möllmann, H, Makkar, R R, Herrmann, H C, Giustino, G, Baldus, S, De Backer, O, Guimarães, A H C, Gullestad, L, Kini, A, von Lewinski, D, Mack, M, Moreno, R, Schäfer, U, Seeger, J, Tchétché, D, Thomitzek, K, Valgimigli, M, Vranckx, P, Welsh, R C, Wildgoose, P, Volkl, A A, Zazula, A, van Amsterdam, R G M, Mehran, R, Windecker, S & GALILEO Investigators 2020, ' A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement ', The New England Journal of Medicine, vol. 382, no. 2, pp. 120-129 . https://doi.org/10.1056/NEJMoa1911425
Dangas, G D, Tijssen, J G P, Wöhrle, J, Søndergaard, L, Gilard, M, Möllmann, H, Makkar, R R, Herrmann, H C, Giustino, G, Baldus, S, de Backer, O, Guimarães, A H C, Gullestad, L, Kini, A, von Lewinski, D, Mack, M, Moreno, R, Schäfer, U, Seeger, J, Tchétché, D, Thomitzek, K, Valgimigli, M, Vranckx, P, Welsh, R C, Wildgoose, P, Volkl, A A, Zazula, A, van Amsterdam, R G M, Mehran, R, Windecker, S & GALILEO Investigators 2020, ' A controlled trial of rivaroxaban after transcatheter aortic-valve replacement ', New England Journal of Medicine, vol. 382, no. 2, pp. 120-129 . https://doi.org/10.1056/NEJMoa1911425

Background Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. Methods We randomly assigned 1644 patients without an established indication for oral anti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c3ae5ab6f694fae00da8d0f58ce2f3